Table 5.

Genetic linkage of grlA mutations and resistance by transformation: incross of grlA +

DonorRecipientMIC (μg/ml) fora:% Susceptible (no. of susceptible strains/total no. of transformants)
RecipientSusceptible transformants
StrainGenotypeStrainGenotypePRFXCPFXPRFXCPFX
ISP2133 trp-489Ω(chr::Tn917lac)2 P4 grlA(Arg43Cys)0.0161.00.0080.2521 (15/70)
P6 grlA (Pro157Leu) gyrA(Met538Ile)0.0321.00.0080.2539 (37/95)
P10 grlA(Ala176Thr)0.0321.00.0080.12530 (31/104)
P21 grlA(Asp69Tyr)0.0321.00.0080.2524 (24/100)
MT5224c4 grlA(Ser80Phe)0.0321.00.0080.2521 (8/38)
ISP2134 thrB494Ω(chr::Tn917lac)1 P4 grlA(Arg43Cys)0.0161.00.0080.257 (7/100)
P6 grlA (Pro157Leu) gyrA(Met538Ile)0.0321.00.0080.12510 (12/115)
P10 grlA(Ala176Thr)0.0321.00.0080.1259 (13/144)
P21 grlA(Asp69Tyr)0.0321.00.0080.259 (9/100)
MT5224c4 grlA(Ser80Phe)0.0321.00.0080.255 (8/171)
  • a Abbreviations: PRFX, premafloxacin; CPFX, ciprofloxacin.